Predicting recurrence-free survival after surgery for GIST

Lancet Oncol. 2009 Nov;10(11):1025. doi: 10.1016/S1470-2045(09)70267-0. Epub 2009 Sep 28.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Benzamides
  • Chemotherapy, Adjuvant
  • Digestive System Surgical Procedures*
  • Disease-Free Survival
  • Gastrointestinal Stromal Tumors / drug therapy
  • Gastrointestinal Stromal Tumors / mortality
  • Gastrointestinal Stromal Tumors / secondary
  • Gastrointestinal Stromal Tumors / surgery*
  • Humans
  • Imatinib Mesylate
  • Mitotic Index
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Nomograms*
  • Patient Selection*
  • Piperazines / therapeutic use
  • Predictive Value of Tests
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrimidines / therapeutic use
  • Reproducibility of Results
  • Risk Assessment
  • Time Factors
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate